FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

127 letters match. Newest first.

  1. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  2. Zhejiang Gaorong Cosmetic Co., Ltd.

    FDA cited Zhejiang Gaorong Cosmetic for OTC drug CGMP violations in component testing and quality unit oversight.

    High risk
  3. Jiangmen Shuizirun Sanitary Articles Co., Ltd.

    FDA warns Chinese OTC drug maker Jiangmen Shuizirun for labeling products sterile without sterilizing them or testing for sterility.

    High risk
  4. Babikian Healthcare Products CJSC

    FDA warns Babikian Healthcare Products over manufacturing quality failures for over-the-counter drugs, including missing identity and finished-product testing.

    High risk
  5. Bentley Laboratories LLC

    Bentley Laboratories LLC was cited for CGMP violations and for marketing unapproved acne drugs.

    High risk
  6. Stream2Sea, LLC

    FDA found Stream2Sea, an OTC drug maker in Bowling Green, Florida, released drug batches without finished-product testing, raw material identity testing, or validated cleaning.

    Medium
  7. Happy Farm Botanicals, Inc.

    Happy Farm Botanicals, an OTC drug maker in Hyattsville, MD, cited for skipping ingredient identity tests and stability testing, repeat violations.

    High risk
  8. Thomas Brunner Hygiene GmbH

    Thomas Brunner Hygiene GmbH's syNeo antiperspirants are unapproved new drugs and were made without adequate manufacturing testing and validation.

    High risk
  9. AHC Products, Inc.

    AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.

    High risk
  10. Amie Health, Inc. dba Amie

    FDA warned telehealth seller Amie Health that its website misbrands compounded semaglutide and tirzepatide with false and misleading claims.

    Medium
  11. FITISH

    FDA warned FITISH over misleading website claims for compounded semaglutide and tirzepatide, including labels suggesting it is the compounder.

    Low
  12. Macau-Union Pharmaceutical Limited

    Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.

    High risk
  13. GSC Products, LLC

    FDA told GSC Products its Sinus Plumber headache nasal spray is an unapproved new drug sold online without FDA approval.

    High risk
  14. Pro Numb Tattoo Numbing Spray, LLC

    FDA cited Pro Numb Tattoo Numbing Spray for selling unapproved, misbranded numbing drugs and manufacturing quality failures after a November 2025 inspection.

    High risk
  15. Apothecary Pharma, LLC

    FDA warns Apothecary Pharma, an outsourcing facility, that its sterile compounded drugs were made under insanitary conditions.

    High risk
  16. Premium Health Management Inc. dba Premium Health

    FDA warns Premium Health over misleading website claims for compounded semaglutide and tirzepatide.

    Low
  17. Kare Solutions, LLC dba Zappy

    FDA warned Zappy that its website falsely suggested it compounds semaglutide, tirzepatide, and liraglutide and made misleading approval-like claims.

    Low
  18. Peaks Curative, LLC dba Peaks

    FDA warned Peaks Curative over false or misleading website claims for compounded (pharmacy-made) semaglutide, including implied FDA approval.

    Low
  19. MaxLife Technologies Inc. dba Maxlife

    FDA told telehealth seller Maxlife its website falsely implied Maxlife compounds semaglutide and tirzepatide and that the drugs are FDA-approved.

    Medium
  20. Better Health Labs, Inc. dba Measured

    FDA warned telehealth seller Measured its website misbranded compounded semaglutide and tirzepatide by implying it made them and that they were FDA-approved.

    Medium
  21. FitRX, LLC dba FitRx

    FitRx's website misbranded compounded semaglutide and tirzepatide with false and misleading claims, FDA says.

    Medium
  22. Signature Formulations, LLC

    FDA says Signature Formulations made OTC drugs on shared equipment without adequate controls, risking hormone contamination.

    High risk
  23. Cohance Lifesciences Limited

    Cohance Lifesciences, a finished-drug maker, was cited for inadequate investigations and dirty shared equipment that caused cross-contamination.

    High risk
  24. Fulijaya Manufacturing SDN. BHD.

    Fulijaya Manufacturing in Malaysia failed CGMP (drug manufacturing rules) for OTC drugs, with missing lab data, flawed microbial tests, and weak stability data.

    High risk
  25. Guangdong Renhe Guozhuang Biotechnology Co., Ltd.

    FDA warns Guangdong Renhe Guozhuang Biotechnology over CGMP failures in OTC drug manufacturing.

    High risk
  26. CDL Services, Inc. DBA Technichem

    FDA warned CDL Services (Technichem), an Anaheim OTC drug maker, that it released hand sanitizer and hand soap batches without testing.

    High risk
  27. Sinsin Pharmaceutical Co., Ltd.

    FDA warned Sinsin Pharmaceutical that two Korean topical pain relievers sold in the US are unapproved and misbranded drugs.

    High risk
  28. Kath Khemicals LLC

    FDA: Kath Khemicals, an OTC hand soap maker in Macomb, MI, released drugs without finished-product or glycerin identity testing.

    High risk
  29. Guangxi Yulin Pharmaceutical Group Co. Ltd.

    FDA warned Guangxi Yulin Pharmaceutical Group that its OTC drugs lacked release testing and had data integrity failures.

    High risk
  30. Health and Natural Beauty USA Corp.

    FDA warns Health and Natural Beauty USA over CGMP failures and unapproved, misbranded SprinJene OTC toothpastes, including children’s products.

    High risk
  31. cheaptrustedpharmacy.com

    cheaptrustedpharmacy.com sells unapproved, misbranded prescription drugs to U.S. consumers online, FDA warns.

    High risk
  32. FWD Care, Inc. dba FWD

    FDA warned telehealth company FWD Care that its website claims for compounded semaglutide and tirzepatide drugs are false or misleading.

    Medium
  33. Dermacare LLC dba BlueChew

    FDA warned BlueChew over website claims that its compounded sildenafil and tadalafil are the same as Viagra and Cialis.

    High risk
  34. iVisitDoc, Inc. dba iVisitDoc

    FDA warns iVisitDoc over website claims that compounded semaglutide is equivalent to Wegovy and Ozempic, calling the drugs misbranded.

    Medium
  35. Hello Cake, Inc. dba Hello Cake

    FDA warns Hello Cake, an online telehealth seller, that its website misbrands compounded sildenafil and tadalafil ED drugs as equivalent to Viagra and Cialis.

    Medium
  36. Body Good Studio

    FDA warned Body Good Studio over its website selling compounded semaglutide with a false claim that it matches Ozempic and Wegovy.

    High risk
  37. Matthew Stern, CEO MyStart Health LLC.

    FDA warns MyStart Health over 'Generic Ozempic' claims for compounded semaglutide.

    Low
  38. Curex

    FDA warned Curex that its website ads for compounded semaglutide and tirzepatide are false or misleading.

    High risk
  39. Hikal Limited

    FDA warned India's Hikal Limited that unresolved metal-particle complaints in its APIs and weak supplier oversight make its active ingredients adulterated.

    High risk
  40. Kalani AB dba Kalani Sunwear

    FDA warns Kalani AB that its Sun Mousse SPF 50 sunscreen is an unapproved, misbranded drug for US sale.

    High risk
  41. Glenmark Pharmaceuticals Limited

    FDA warns Glenmark over unresolved dissolution failures and inadequate investigations at its Pithampur, India drug plant.

    High risk
  42. Scope Health Inc

    FDA says Scope Health sold unapproved OTC eye drugs online and misbranded several products.

    High risk
  43. Revitalize Energy, Inc.

    FDA warned Revitalize Energy that its Revitalize Energizing Eye Drops are an unapproved new drug and misbranded.

    High risk
  44. Thea Pharma, Inc.

    FDA warns Thea Pharma that IVIZIA OTC lubricant eye drops are an unapproved and misbranded new drug.

    High risk
  45. EyeTech One, LLC

    FDA warns EyeTech One that its EYELIVIO lubricant eye ointment is an unapproved new drug and misbranded.

    Medium
  46. Xtreme Tools International, Inc.

    FDA warned Xtreme Tools International after an inspection found manufacturing-rule failures for OTC topical drugs, including missing ingredient and batch testing.

    High risk
  47. Dynamic Blending Specialists, Inc.

    FDA cited Dynamic Blending Specialists for manufacturing failures in OTC drugs and an unapproved, misbranded oral antiseptic.

    High risk
  48. Zhejiang Huahai Pharmaceutical Co., Ltd.

    FDA warns Zhejiang Huahai Pharmaceutical over CGMP violations including dirty equipment, aseptic-area tape, and data integrity issues.

    High risk
  49. Horizon Tool Inc.

    FDA warns Horizon Tool over manufacturing-rule violations for AllShield E2 Sanitizing Hand Soap.

    High risk
  50. Zhejiang Easyclean Daily Chemical Co., Ltd

    FDA warned Zhejiang Easyclean Daily Chemical that its OTC drugs lacked required testing and manufacturing controls.

    High risk